Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The goal of this phase II randomized open label study is to compare the rate of complete remission (CR) with undetectable minimal residual disease (uMRD) obtained with zanubrutinib in combination with obinutuzumab with two different schedules of administration of obinutuzumab (starting obinutuzumab at cycle 2 or 12 months) in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). There is scarce information about which is the most appropriate schedule of combining the BTKi and the anti-CD20 monoclonal antibody, and whether treatment can be sa

Trial Details

NCT ID
NCT06544785
Phase
PHASE2
Sponsor
PETHEMA Foundation
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Zanubrutinib Oral Product
  • Obinutuzumab
Locations (sample)
  • Alicante, Spain|38.34517,-0.48149
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Adult patients with previously untreated CLL defined following IWCLL criteria (Hallek, 2018).
  • Must understand and voluntarily sign an informed consent form.
  • Age ≥ 18 years at the time of signing the informed consent form and must be able to adhere to the study visit schedule and other protocol requireme…
  • Must have a documented diagnosis of CLL or SLL \[IWCLL guidelines for diagnosis and treatment of CLL (Hallek, 2018)\] meeting at least one of the f…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →